Loading…
Mammographic breast density changes after 1 year of tibolone use
Hormone replacement therapy (HRT) is widely used with a large variety of regimens and medications. For each of these regimens the goal is the same but there is always a fear about side effects, especially on breast. Mammographic screening is a standard tool for all women receiving hormone replacemen...
Saved in:
| Published in: | Maturitas 2004-06, Vol.48 (2), p.133-136 |
|---|---|
| Main Authors: | , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c397t-268a0a21ad208e6e97f0a97fe32c56b776d42196ce426eaa852cf0a9fa927f903 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c397t-268a0a21ad208e6e97f0a97fe32c56b776d42196ce426eaa852cf0a9fa927f903 |
| container_end_page | 136 |
| container_issue | 2 |
| container_start_page | 133 |
| container_title | Maturitas |
| container_volume | 48 |
| creator | Kutlu, Tayfun Fiçicioǧlu, Cem Başaran, Toygun Başaran, Esra Topaloğlu, Tümay |
| description | Hormone replacement therapy (HRT) is widely used with a large variety of regimens and medications. For each of these regimens the goal is the same but there is always a fear about side effects, especially on breast. Mammographic screening is a standard tool for all women receiving hormone replacement therapy. Breast density is very important, because it interferes with the sensitivity of the evaluation and it is also a predictor of malignity.
Objective: We planned a study to investigate the effects of tibolone on mammographic breast density.
Design and methods: We studied 70 postmenopausal women who started tibolone therapy (2.5
mg per day) after initial mammography and blood samples taken for biochemical examinations. None of the women used any hormone replacement therapy before. Eleven of them either discontinued the therapy or lost contact. After 1 year, we evaluated 59 women by mammographic status, using Wolfe classification. Mammographies were analyzed by two independent radiologists.
Results: Mammographies of 59 women were compared with the initial ones. While in the low density patterns, there was a slight increase (15%;
P |
| doi_str_mv | 10.1016/j.maturitas.2003.08.009 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71978258</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0378512203003141</els_id><sourcerecordid>71978258</sourcerecordid><originalsourceid>FETCH-LOGICAL-c397t-268a0a21ad208e6e97f0a97fe32c56b776d42196ce426eaa852cf0a9fa927f903</originalsourceid><addsrcrecordid>eNqFkLtOxDAQRS0EguXxC-AGuoSx87DTgRAvCUQDtTXrTMCrPBbbQdq_J6tdAR3NTHPu3NFh7ExAKkCUl4u0wzh6FzGkEiBLQacA1Q6bCa2yJBdC7LIZZEonhZDygB2GsACAArJ8nx2IQigJWs3Y1TN23fDucfnhLJ97whB5TX1wccXtB_bvFDg2kTwXfEXo-dDw6OZDO_TEx0DHbK_BNtDJdh-xt7vb15uH5Onl_vHm-imxWaViIkuNgFJgPfVSSZVqAKdBmbRFOVeqrHMpqtJSLktC1IW0a6LBSqqmguyIXWzuLv3wOVKIpnPBUttiT8MYjBKV0rLQE6g2oPVDCJ4as_SuQ78yAsxanlmYH3lmLc-ANpO8KXm6rRjnHdW_ua2tCTjfAhgsto3H3rrwh1O6ApVP3PWGo0nIlyNvgnXUW6qdJxtNPbh_n_kGigORZw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71978258</pqid></control><display><type>article</type><title>Mammographic breast density changes after 1 year of tibolone use</title><source>ScienceDirect Journals</source><creator>Kutlu, Tayfun ; Fiçicioǧlu, Cem ; Başaran, Toygun ; Başaran, Esra ; Topaloğlu, Tümay</creator><creatorcontrib>Kutlu, Tayfun ; Fiçicioǧlu, Cem ; Başaran, Toygun ; Başaran, Esra ; Topaloğlu, Tümay</creatorcontrib><description>Hormone replacement therapy (HRT) is widely used with a large variety of regimens and medications. For each of these regimens the goal is the same but there is always a fear about side effects, especially on breast. Mammographic screening is a standard tool for all women receiving hormone replacement therapy. Breast density is very important, because it interferes with the sensitivity of the evaluation and it is also a predictor of malignity.
Objective: We planned a study to investigate the effects of tibolone on mammographic breast density.
Design and methods: We studied 70 postmenopausal women who started tibolone therapy (2.5
mg per day) after initial mammography and blood samples taken for biochemical examinations. None of the women used any hormone replacement therapy before. Eleven of them either discontinued the therapy or lost contact. After 1 year, we evaluated 59 women by mammographic status, using Wolfe classification. Mammographies were analyzed by two independent radiologists.
Results: Mammographies of 59 women were compared with the initial ones. While in the low density patterns, there was a slight increase (15%;
P<0.05); in the higher density groups, there was a decrease of 25% as observed by one radiologist, and 16% according to the other (
P<0.05). None of the women had a diffuse, high density pattern. There was no statistically significant inter-observer variation between two radiologists (
P>0.05).
Conclusions: Wolfe classification allows easy interpretation of mammographic evaluation and the results are reproducible. Tibolone, as a tissue-specific steroid, does not have an estrogenic effect on breast cells. We found that it might limit, even reverse breast density increase, especially in postmenopausal women with high breast density.</description><identifier>ISSN: 0378-5122</identifier><identifier>EISSN: 1873-4111</identifier><identifier>DOI: 10.1016/j.maturitas.2003.08.009</identifier><identifier>PMID: 15172087</identifier><identifier>CODEN: MATUDK</identifier><language>eng</language><publisher>Shannon: Elsevier Ireland Ltd</publisher><subject>Biological and medical sciences ; Breast - drug effects ; Breast density ; Breast Neoplasms - diagnostic imaging ; Drug Administration Schedule ; Estrogen Receptor Modulators - administration & dosage ; Female ; Genital system. Reproduction ; Gynecology. Andrology. Obstetrics ; Hormone Replacement Therapy ; Humans ; Mammography ; Medical sciences ; Middle Aged ; Norpregnenes - administration & dosage ; Pharmacology. Drug treatments ; Prospective Studies ; Puberal and climacteric disorders (male and female) ; Tibolone</subject><ispartof>Maturitas, 2004-06, Vol.48 (2), p.133-136</ispartof><rights>2003 Elsevier Ireland Ltd</rights><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c397t-268a0a21ad208e6e97f0a97fe32c56b776d42196ce426eaa852cf0a9fa927f903</citedby><cites>FETCH-LOGICAL-c397t-268a0a21ad208e6e97f0a97fe32c56b776d42196ce426eaa852cf0a9fa927f903</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15789074$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15172087$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kutlu, Tayfun</creatorcontrib><creatorcontrib>Fiçicioǧlu, Cem</creatorcontrib><creatorcontrib>Başaran, Toygun</creatorcontrib><creatorcontrib>Başaran, Esra</creatorcontrib><creatorcontrib>Topaloğlu, Tümay</creatorcontrib><title>Mammographic breast density changes after 1 year of tibolone use</title><title>Maturitas</title><addtitle>Maturitas</addtitle><description>Hormone replacement therapy (HRT) is widely used with a large variety of regimens and medications. For each of these regimens the goal is the same but there is always a fear about side effects, especially on breast. Mammographic screening is a standard tool for all women receiving hormone replacement therapy. Breast density is very important, because it interferes with the sensitivity of the evaluation and it is also a predictor of malignity.
Objective: We planned a study to investigate the effects of tibolone on mammographic breast density.
Design and methods: We studied 70 postmenopausal women who started tibolone therapy (2.5
mg per day) after initial mammography and blood samples taken for biochemical examinations. None of the women used any hormone replacement therapy before. Eleven of them either discontinued the therapy or lost contact. After 1 year, we evaluated 59 women by mammographic status, using Wolfe classification. Mammographies were analyzed by two independent radiologists.
Results: Mammographies of 59 women were compared with the initial ones. While in the low density patterns, there was a slight increase (15%;
P<0.05); in the higher density groups, there was a decrease of 25% as observed by one radiologist, and 16% according to the other (
P<0.05). None of the women had a diffuse, high density pattern. There was no statistically significant inter-observer variation between two radiologists (
P>0.05).
Conclusions: Wolfe classification allows easy interpretation of mammographic evaluation and the results are reproducible. Tibolone, as a tissue-specific steroid, does not have an estrogenic effect on breast cells. We found that it might limit, even reverse breast density increase, especially in postmenopausal women with high breast density.</description><subject>Biological and medical sciences</subject><subject>Breast - drug effects</subject><subject>Breast density</subject><subject>Breast Neoplasms - diagnostic imaging</subject><subject>Drug Administration Schedule</subject><subject>Estrogen Receptor Modulators - administration & dosage</subject><subject>Female</subject><subject>Genital system. Reproduction</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Hormone Replacement Therapy</subject><subject>Humans</subject><subject>Mammography</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Norpregnenes - administration & dosage</subject><subject>Pharmacology. Drug treatments</subject><subject>Prospective Studies</subject><subject>Puberal and climacteric disorders (male and female)</subject><subject>Tibolone</subject><issn>0378-5122</issn><issn>1873-4111</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><recordid>eNqFkLtOxDAQRS0EguXxC-AGuoSx87DTgRAvCUQDtTXrTMCrPBbbQdq_J6tdAR3NTHPu3NFh7ExAKkCUl4u0wzh6FzGkEiBLQacA1Q6bCa2yJBdC7LIZZEonhZDygB2GsACAArJ8nx2IQigJWs3Y1TN23fDucfnhLJ97whB5TX1wccXtB_bvFDg2kTwXfEXo-dDw6OZDO_TEx0DHbK_BNtDJdh-xt7vb15uH5Onl_vHm-imxWaViIkuNgFJgPfVSSZVqAKdBmbRFOVeqrHMpqtJSLktC1IW0a6LBSqqmguyIXWzuLv3wOVKIpnPBUttiT8MYjBKV0rLQE6g2oPVDCJ4as_SuQ78yAsxanlmYH3lmLc-ANpO8KXm6rRjnHdW_ua2tCTjfAhgsto3H3rrwh1O6ApVP3PWGo0nIlyNvgnXUW6qdJxtNPbh_n_kGigORZw</recordid><startdate>20040615</startdate><enddate>20040615</enddate><creator>Kutlu, Tayfun</creator><creator>Fiçicioǧlu, Cem</creator><creator>Başaran, Toygun</creator><creator>Başaran, Esra</creator><creator>Topaloğlu, Tümay</creator><general>Elsevier Ireland Ltd</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20040615</creationdate><title>Mammographic breast density changes after 1 year of tibolone use</title><author>Kutlu, Tayfun ; Fiçicioǧlu, Cem ; Başaran, Toygun ; Başaran, Esra ; Topaloğlu, Tümay</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c397t-268a0a21ad208e6e97f0a97fe32c56b776d42196ce426eaa852cf0a9fa927f903</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Biological and medical sciences</topic><topic>Breast - drug effects</topic><topic>Breast density</topic><topic>Breast Neoplasms - diagnostic imaging</topic><topic>Drug Administration Schedule</topic><topic>Estrogen Receptor Modulators - administration & dosage</topic><topic>Female</topic><topic>Genital system. Reproduction</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Hormone Replacement Therapy</topic><topic>Humans</topic><topic>Mammography</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Norpregnenes - administration & dosage</topic><topic>Pharmacology. Drug treatments</topic><topic>Prospective Studies</topic><topic>Puberal and climacteric disorders (male and female)</topic><topic>Tibolone</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kutlu, Tayfun</creatorcontrib><creatorcontrib>Fiçicioǧlu, Cem</creatorcontrib><creatorcontrib>Başaran, Toygun</creatorcontrib><creatorcontrib>Başaran, Esra</creatorcontrib><creatorcontrib>Topaloğlu, Tümay</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Maturitas</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kutlu, Tayfun</au><au>Fiçicioǧlu, Cem</au><au>Başaran, Toygun</au><au>Başaran, Esra</au><au>Topaloğlu, Tümay</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mammographic breast density changes after 1 year of tibolone use</atitle><jtitle>Maturitas</jtitle><addtitle>Maturitas</addtitle><date>2004-06-15</date><risdate>2004</risdate><volume>48</volume><issue>2</issue><spage>133</spage><epage>136</epage><pages>133-136</pages><issn>0378-5122</issn><eissn>1873-4111</eissn><coden>MATUDK</coden><abstract>Hormone replacement therapy (HRT) is widely used with a large variety of regimens and medications. For each of these regimens the goal is the same but there is always a fear about side effects, especially on breast. Mammographic screening is a standard tool for all women receiving hormone replacement therapy. Breast density is very important, because it interferes with the sensitivity of the evaluation and it is also a predictor of malignity.
Objective: We planned a study to investigate the effects of tibolone on mammographic breast density.
Design and methods: We studied 70 postmenopausal women who started tibolone therapy (2.5
mg per day) after initial mammography and blood samples taken for biochemical examinations. None of the women used any hormone replacement therapy before. Eleven of them either discontinued the therapy or lost contact. After 1 year, we evaluated 59 women by mammographic status, using Wolfe classification. Mammographies were analyzed by two independent radiologists.
Results: Mammographies of 59 women were compared with the initial ones. While in the low density patterns, there was a slight increase (15%;
P<0.05); in the higher density groups, there was a decrease of 25% as observed by one radiologist, and 16% according to the other (
P<0.05). None of the women had a diffuse, high density pattern. There was no statistically significant inter-observer variation between two radiologists (
P>0.05).
Conclusions: Wolfe classification allows easy interpretation of mammographic evaluation and the results are reproducible. Tibolone, as a tissue-specific steroid, does not have an estrogenic effect on breast cells. We found that it might limit, even reverse breast density increase, especially in postmenopausal women with high breast density.</abstract><cop>Shannon</cop><pub>Elsevier Ireland Ltd</pub><pmid>15172087</pmid><doi>10.1016/j.maturitas.2003.08.009</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0378-5122 |
| ispartof | Maturitas, 2004-06, Vol.48 (2), p.133-136 |
| issn | 0378-5122 1873-4111 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71978258 |
| source | ScienceDirect Journals |
| subjects | Biological and medical sciences Breast - drug effects Breast density Breast Neoplasms - diagnostic imaging Drug Administration Schedule Estrogen Receptor Modulators - administration & dosage Female Genital system. Reproduction Gynecology. Andrology. Obstetrics Hormone Replacement Therapy Humans Mammography Medical sciences Middle Aged Norpregnenes - administration & dosage Pharmacology. Drug treatments Prospective Studies Puberal and climacteric disorders (male and female) Tibolone |
| title | Mammographic breast density changes after 1 year of tibolone use |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T10%3A50%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mammographic%20breast%20density%20changes%20after%201%20year%20of%20tibolone%20use&rft.jtitle=Maturitas&rft.au=Kutlu,%20Tayfun&rft.date=2004-06-15&rft.volume=48&rft.issue=2&rft.spage=133&rft.epage=136&rft.pages=133-136&rft.issn=0378-5122&rft.eissn=1873-4111&rft.coden=MATUDK&rft_id=info:doi/10.1016/j.maturitas.2003.08.009&rft_dat=%3Cproquest_cross%3E71978258%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c397t-268a0a21ad208e6e97f0a97fe32c56b776d42196ce426eaa852cf0a9fa927f903%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=71978258&rft_id=info:pmid/15172087&rfr_iscdi=true |